Long-term follow-up study for medulloblastoma survivors treated with radiation
Part of Cancer clinical trials.
This study looks at the long-term health of people who were treated for medulloblastoma with craniospinal radiation at St. Jude Children's Research Hospital. It aims to understand how they are doing years after treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with medulloblastoma between ages 3 and 22, or between 22 and 44 if you have a specific genetic subtype called SHH.
- You received radiation therapy as part of the SJMB12 protocol at St. Jude.
- It has been at least 5 years since you started radiation and your cancer has not come back or gotten worse.
- You or your legal guardian can agree to take part, and you are willing to sign up for the main SJLIFE study as well.
- You can choose to do some or all of the study tests — you don't have to do everything to take part.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard treatments for a type of brain tumor called SHH-activated medulloblastoma in children under 5. The goal is to see which treatment better protects thinking and learning skills over time.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This study follows people who were treated for childhood cancer and compares them with similar adults who did not have that childhood cancer. It aims to learn about long-term health and especially walking or mobility issues over time, using check-ins that may include a mobility assessment.
This study checks long-term health after receiving a gene-modified cell therapy through a St. Jude study. It helps doctors understand the treatment’s lasting effects and safety over time.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.